Information  X 
Enter a valid email address

GlaxoSmithKline PLC (GSK)

  Print      Mail a friend       Annual reports

Tuesday 27 November, 2018

GlaxoSmithKline PLC

Block listing Interim Review

RNS Number : 6693I
GlaxoSmithKline PLC
27 November 2018
 

 

 

 

BLOCK LISTING SIX MONTHLY RETURN

 

Information provided on this form must be typed or printed electronically and provided to an ris.

 

Date: 27 November 2018

 

Name of applicant:

GlaxoSmithKline plc

Name of scheme:

GlaxoSmithKline plc 2009 Deferred Annual Bonus Plan

Period of return:

From:

1 May 2018

To:

31 October 2018

Balance of unallotted securities under scheme(s) from previous return:

Previous balance: 33,863*

Restated balance: -27,669

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

575,000

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

0

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

547,331

         

 

Name of contact:

Victoria Whyte

Telephone number of contact:

020 8047 5000

 

*Due to clerical error the opening balance has been restated.

 

 

 

BLOCK LISTING SIX MONTHLY RETURN

 

Information provided on this form must be typed or printed electronically and provided to an ris.

 

Date: 27 November 2018

 

Name of applicant:

GlaxoSmithKline plc

Name of scheme:

GlaxoSmithKline Share Option Plan - Ordinary Shares

Period of return:

From:

1 May 2018

To:

31 October 2018

Balance of unallotted securities under scheme(s) from previous return:

Previous balance: 2,693,951*

Restated balance: 2,755,483

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

532,131

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

2,223,352

         

 

Name of contact:

Victoria Whyte

Telephone number of contact:

020 8047 5000

 

*Due to clerical error the opening balance has been restated.

 

 

 

BLOCK LISTING SIX MONTHLY RETURN

 

Information provided on this form must be typed or printed electronically and provided to an ris.

 

Date: 27 November 2018

 

Name of applicant:

GlaxoSmithKline plc

Name of scheme:

GlaxoSmithKline Share Option Plan - ADS

Period of return:

From:

1 May 2018

To:

31 October 2018

Balance of unallotted securities under scheme(s) from previous return:

7,909,994

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

573,898

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

7,336,096

         

 

Name of contact:

Victoria Whyte

Telephone number of contact:

020 8047 5000

 

 

BLOCK LISTING SIX MONTHLY RETURN

 

Information provided on this form must be typed or printed electronically and provided to an ris.

 

Date: 27 November 2018

 

Name of applicant:

GlaxoSmithKline plc

Name of scheme:

GlaxoSmithKline plc Share Save Plan 2012

Period of return:

From:

1 May 2018

To:

31 October 2018

Balance of unallotted securities under scheme(s) from previous return:

827,306

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

5,000,000

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

154,683

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

5,672,623

         

 

Name of contact:

Victoria Whyte

Telephone number of contact:

020 8047 5000

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
BLRZMMZMKNZGRZM

a d v e r t i s e m e n t